Skip to main content

Table 5 Indirect comparison results: duloxetine vs. pregabalin.

From: Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain

Outcome Indirect treatment comparison (δ)
Mean (median)
95% CI for δ Between-study variance (τ 2)
Mean (median)
95% CI for τ 2
Efficacy     
Reduction in 24-hour pain intensity -0.248 (0.248) (-0.667;0.162) 0.052 (0.024) (0.001;0.252)
Response 0.033 (0.034) (-0.393;0.451) 0.075 (0.052) (0.001;0.287)
PGI-I/PGI-C 0.542 (0.545) (0.016;1.060) 0.025 (0.009) (0.001;0.151)
Tolerability     
Premature study discontinuation due to:     
- Lack of efficacy -0.251 (-0.235) (-1.288;0.717) 0.058 0.015) (0.001;0.381)
- Adverse events 0.152 (0.154) (-0.505;0.790) 0.039 (0.012) (0.001;0.243)
- Other -0.068 (-0.069) (-0.735;0.589) 0.045 (0.013) (0.001;0.281)
Diarrhoea 0.886 (0.885) (-0.414; 2.183) 0.248 (0.050) (0.001; 1.628)
Dizziness -1.084 (-1.074) (-1.903; -0.317) 0.075 (0.020) (0.001; 0.477)
Headache 0.700 (0.704) (-0.078; 1.458) 0.037 (0.011) (0.001; 0.235)
Somnolence -0.554 (-0.552) (-1.458; 0.328) 0.052 (0.013) (0.001; 0.347)
  1. Note:
  2. δ is the mean difference in treatment effect between DLX and each comparator.
  3. τ 2 is between-study heterogeneity.